Clinical effects of different blood management strategies in total hip arthroplasty: a report of 1998 cases

Guo-rui CAO,Qiang HUANG,Yi-ting LEI,Shao-yun ZHANG,Bin XU,Fu-xing PEI
DOI: https://doi.org/10.3969/j.issn.2095-252X.2017.12.003
2017-01-01
Abstract:Objective To evaluate the clinical effects of erythropoietin, iron and multiple boluses of intravenous tranexamic acid ( IV-TXA ) in patients following primary total hip arthroplasty ( THA ). Methods A large, single-center, retrospective study was done in 1998 patients who underwent primary THA from May 2014 to January 2017. Group A received 20 mg / kg IV-TXA 5 - 10 minutes before skin incision. Group B received erythropoietin and iron supplement on the basis of Group A. Group C received 20 mg / kg IV-TXA before skin incision and 1 g IV-TXA 3, 6, 12, 24 hours later on the basis of Group B. Total blood loss, allogenic transfusion rate, hemoglobin and hematocrit drop were compared. Results Comparing Group A, B, C, there were statistical differences in total blood loss ( 1102.0 ± 503.7 ) vs ( 937.0 ± 441.9 ) vs ( 774.5 ± 380.6 ) ml, allogenic transfusion rate ( 7.3% vs 4.1% vs 1.6% ), hemoglobin ( 23.8 ± 12.4 ) vs ( 18.3 ± 10.8 ) vs ( 16.1 ± 10.3 ) g / L and hematocrit ( 0.068 ± 0.038 ) vs ( 0.056 ± 0.036 ) vs ( 0.048 ± 0.036 ) drop on postoperative day 1, hemoglobin ( 12.1 ± 16.3 ) vs ( 10.1 ± 8.3 ) vs ( 7.5 ± 9.2 ) g / L and hematocrit ( 0.033 ± 0.027 ) vs ( 0.030 ± 0.025 ) vs ( 0.026 ± 0.019 ) drop on postoperative day 3 among the three groups ( P = 0.002 ). The total blood loss, transfusion rate, hemoglobin and hematocrit drop of Group C were lower than those of Group A, B. The transfusion rate was 7.3%, 4.1% and 1.6% in Group A, B and C. The difference was significant ( P < 0.001 ). Conclusions Application of erythropoietin and iron can reduce blood loss and allogenic transfusion rate in patients following THA. Patients can gain a smaller decline of Hb and blood loss combining with multiple boluses of IV-TXA.
What problem does this paper attempt to address?